<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02134249</url>
  </required_header>
  <id_info>
    <org_study_id>khalid-ahmed</org_study_id>
    <nct_id>NCT02134249</nct_id>
  </id_info>
  <brief_title>Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome</brief_title>
  <acronym>infertility</acronym>
  <official_title>Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of oral Diosmin to oral Cabergoline in the
      prevention of ovarian hyperstimulation syndrome (OHSS) in high-risk women underwent
      intracytoplasmic sperm injection (ICSI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two hundred women at risk of ovarian hyperstimulation syndrome during ICSI cycles will be
      randomly scheduled into two equal groups. In group A, (Diosmin group), 2 tab / 8 hs Diosmin (
      500mg) will be given at day of HCG injection and for 2 weeks ; while in group B (Cabergoline
      group), 1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for eight
      days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with ovarian hyperstimulation syndrome (OHSS)</measure>
    <time_frame>every week for eight weeks</time_frame>
    <description>Diagnosis of OHSS was made according to the criteria of Golan et al.. Mild OHSS was classified as: Grade 1 (abdominal distension and discomfort) and Grade 2 (features of grade 1 plus nausea, vomiting and/or diarrhea; ovaries are enlarged from 5 to 12 cm), moderate OHSS as Grade 3 (features of mild OHSS plus ultrasonic evidence of ascites), severe OHSS as Grade 4 (features of moderate OHSS plus evidence of ascites and/or hydrothorax and breathing difficulties) and Grade 5 (all of the above, plus change in the blood volume, increased blood viscosity due to hemoconcentration, coagulation abnormality, and diminished renal perfusion and function).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pregnancy rate</measure>
    <time_frame>14 days after embryos transfer</time_frame>
    <description>Î²-hCG (serum hCG test) will be checked 14 days after embryos transfer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Group A (Diosmin group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In group A, (Diosmin group), 2 tab / 8 hs Diosmin ( 500mg) will be given from at day of HCG injection and for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B(Cabergoline group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>while in group B (Cabergoline group), 1 tab/day Cabergoline(Dostinex)( 0.5 mg) will be given at day of HCG injection and for 8 days .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diosmin</intervention_name>
    <description>2 tab / 8 hs Diosmin ( 500mg) will be given at day of HCG injection and for14 days</description>
    <arm_group_label>Group A (Diosmin group)</arm_group_label>
    <other_name>Daflon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabergoline</intervention_name>
    <description>1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days</description>
    <arm_group_label>Group B(Cabergoline group)</arm_group_label>
    <other_name>Dostinex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: infertile women undergoing intracytoplasmic sperm injection or
        polycystic ovarin syndrome (PCO) with one of the following:

          1. Presence of more than 20 follicles by ultrasound

          2. E2 more than 3000 pg/ml

          3. Retrieval of more than 15 follicles

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>khalid mohamed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics and Gynecology, Benha University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ahmed samy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics and Gynecology, Benha University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banha Universty</name>
      <address>
        <city>Banha</city>
        <state>El Qalubia</state>
        <zip>13518</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benha univesity hospital</name>
      <address>
        <city>Benha</city>
        <state>El Qualyobia</state>
        <zip>13518</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2014</study_first_submitted>
  <study_first_submitted_qc>May 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2014</study_first_posted>
  <last_update_submitted>January 29, 2016</last_update_submitted>
  <last_update_submitted_qc>January 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>khalid abd aziz mohamed</investigator_full_name>
    <investigator_title>lecturer of ob/gyn</investigator_title>
  </responsible_party>
  <keyword>infertility</keyword>
  <keyword>ICSI</keyword>
  <keyword>OHSS</keyword>
  <keyword>Diosmin</keyword>
  <keyword>Cabergoline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cabergoline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>with other researcher on research gate</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

